Imatinib
Adjuvant Study 2 (SSG XVIII)
Novartis · Phase 3 · Completed · Enrollment 400
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg for 36 months | n/r |
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Imatinib
Novartis · Phase 3 · Completed · Enrollment 400
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg for 36 months | n/r |
A count stays a count. This page does not turn a count into a percent.